207 related articles for article (PubMed ID: 7973686)
1. Risk from low-dose exposures.
Zendzian RP
Science; 1994 Nov; 266(5188):1142-3. PubMed ID: 7973686
[No Abstract] [Full Text] [Related]
2. Risk from low-dose exposures.
Portier CJ; Lucier GW; Edler L
Science; 1994 Nov; 266(5188):1141-2. PubMed ID: 7973685
[No Abstract] [Full Text] [Related]
3. Risk from low-dose exposures.
Monro AM
Science; 1994 Nov; 266(5188):1141. PubMed ID: 7973684
[No Abstract] [Full Text] [Related]
4. Risk from low-dose exposures.
Strauss BS
Science; 1994 Nov; 266(5188):1143-4. PubMed ID: 7973688
[No Abstract] [Full Text] [Related]
5. So carcinogens have thresholds: how do we decide what exposure levels should be considered safe?
Wilson JD
Risk Anal; 1997 Feb; 17(1):1-3. PubMed ID: 9131822
[No Abstract] [Full Text] [Related]
6. A molecular approach to cancer risk.
Stone R
Science; 1995 Apr; 268(5209):356-7. PubMed ID: 7716533
[No Abstract] [Full Text] [Related]
7. Cancer risk assessment: historical perspectives, current issues, and future directions.
Velazquez SF; Schoeny R; Rice GE; Cogliano VJ
Drug Chem Toxicol; 1996 Aug; 19(3):161-85. PubMed ID: 8933022
[No Abstract] [Full Text] [Related]
8. [A regulatory view on the article: Risk evaluation of carcinogens and their threshold levels, part I-III].
Dieter HH; Konietzka R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Sep; 49(9):921-5. PubMed ID: 16953360
[No Abstract] [Full Text] [Related]
9. [What is the understanding of the scientific basis and the regulatory toxicology associated with the term "not appreciable " in the risk evaluation of carcinogens].
Dieter HH; Konietzka R; Neumann HG
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Aug; 50(8):1084-5. PubMed ID: 17676413
[No Abstract] [Full Text] [Related]
10. Risk assessments of low-level exposures.
Abelson PH
Science; 1994 Sep; 265(5178):1507. PubMed ID: 7832844
[No Abstract] [Full Text] [Related]
11. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
12. To MTBE or not to MTBE.
Environ Health Perspect; 1994 Nov; 102(11):913. PubMed ID: 9766950
[No Abstract] [Full Text] [Related]
13. Use of 'secondary mechanism' in the regulation of carcinogens; a chronology.
Scheuplein RJ
Cancer Lett; 1995 Jun; 93(1):103-12. PubMed ID: 7600537
[TBL] [Abstract][Full Text] [Related]
14. A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens.
Felter SP; Conolly RB; Bercu JP; Bolger PM; Boobis AR; Bos PM; Carthew P; Doerrer NG; Goodman JI; Harrouk WA; Kirkland DJ; Lau SS; Llewellyn GC; Preston RJ; Schoeny R; Schnatter AR; Tritscher A; van Velsen F; Williams GM
Crit Rev Toxicol; 2011 Jul; 41(6):507-44. PubMed ID: 21591905
[TBL] [Abstract][Full Text] [Related]
15. Risk assessments of low-level exposures.
Smith SJ; Chen AT; Caudill SP; Wetterhall SF; Sever LE
Science; 1995 Feb; 267(5198):603-4. PubMed ID: 7839131
[No Abstract] [Full Text] [Related]
16. Assessing cancer risks from short-term exposures in children.
Ginsberg GL
Risk Anal; 2003 Feb; 23(1):19-34. PubMed ID: 12635720
[TBL] [Abstract][Full Text] [Related]
17. Testing for carcinogens: shift from animals to automation gathers steam--slowly.
Schmidt C
J Natl Cancer Inst; 2009 Jul; 101(13):910-2. PubMed ID: 19549960
[No Abstract] [Full Text] [Related]
18. Environmental health. Second look at arsenic finds higher risk.
Kaiser J
Science; 2001 Sep; 293(5538):2189. PubMed ID: 11567118
[No Abstract] [Full Text] [Related]
19. Comparison of human exposures to selected chemicals with thresholds from NTP carcinogenicity studies in rodents.
Waddell WJ
Hum Exp Toxicol; 2003 Sep; 22(9):501-6. PubMed ID: 14580010
[TBL] [Abstract][Full Text] [Related]
20. Toxicology. Just how bad is dioxin?
Kaiser J
Science; 2000 Jun; 288(5473):1941-4. PubMed ID: 10877704
[No Abstract] [Full Text] [Related]
[Next] [New Search]
